Historical source coverage

2012

82 selected records with a cited source date in 2012. This archive is selective and does not imply continuous monitoring or complete historical coverage.

Explore 2012 by record type

3 types

December 2012

10 records

Clinical trials · Glatiramer acetate

ClinicalTrials.gov record NCT00811395

PeptideScanner retained ClinicalTrials.gov record NCT00811395 at 2026-11-16T17:42:50.457Z. Its registry update date was 2012-12-31, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.

Source: ClinicalTrials.gov ↗

→

Clinical trials · Peginesatide

ClinicalTrials.gov record NCT00097747

PeptideScanner retained ClinicalTrials.gov record NCT00097747 at 2026-11-16T17:45:11.119Z. Its registry update date was 2012-12-21, and PeptideScanner's reviewed identity mapping was peginesatide.

Source: ClinicalTrials.gov ↗

→

Clinical trials · Peginesatide

ClinicalTrials.gov record NCT00228436

PeptideScanner retained ClinicalTrials.gov record NCT00228436 at 2026-11-16T17:45:11.119Z. Its registry update date was 2012-12-21, and PeptideScanner's reviewed identity mapping was peginesatide.

Source: ClinicalTrials.gov ↗

→

Clinical trials · Peginesatide

ClinicalTrials.gov record NCT00228449

PeptideScanner retained ClinicalTrials.gov record NCT00228449 at 2026-11-16T17:45:11.119Z. Its registry update date was 2012-12-21, and PeptideScanner's reviewed identity mapping was peginesatide.

Source: ClinicalTrials.gov ↗

→

Clinical trials · Peginesatide

ClinicalTrials.gov record NCT00272662

PeptideScanner retained ClinicalTrials.gov record NCT00272662 at 2026-11-16T17:45:11.119Z. Its registry update date was 2012-12-21, and PeptideScanner's reviewed identity mapping was peginesatide.

Source: ClinicalTrials.gov ↗

→

Clinical trials · Nesiritide

ClinicalTrials.gov record NCT00252187

PeptideScanner retained ClinicalTrials.gov record NCT00252187 at 2026-11-16T01:39:41.882Z. Its registry update date was 2012-12-20, and PeptideScanner's reviewed identity mapping was nesiritide.

Source: ClinicalTrials.gov ↗

→

Regulatory · Desmopressin

Federal Register notice 2012-30308

The Federal Register published notice 2012-30308, attributed to FDA and its parent HHS department, on 2012-12-17. Its official title is “Draft and Revised Draft Guidances for Industry Describing Product-Specific Bioequivalence Recommendations; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Desmopressin.

Source: Federal Register via GovInfo ↗

→

Regulatory · Pasireotide

Drugs@FDA application NDA200677

The official Drugs@FDA dataset lists original submission 1 for NDA 200677 with status AP dated 2012-12-14, and names pasireotide diaspartate among the application record's active ingredients.

Source: Drugs@FDA via openFDA ↗

→

November 2012

17 records

Clinical trials · Eptifibatide

ClinicalTrials.gov record NCT00426751

PeptideScanner retained ClinicalTrials.gov record NCT00426751 at 2026-11-15T21:59:29.646Z. Its registry update date was 2012-11-27, and PeptideScanner's reviewed identity mapping was eptifibatide.

Source: ClinicalTrials.gov ↗

→

Clinical trials · Octreotide

ClinicalTrials.gov record NCT00426153

PeptideScanner retained ClinicalTrials.gov record NCT00426153 at 2026-07-30T22:14:20.912Z. Its registry update date was 2012-11-21, and PeptideScanner's reviewed identity mapping was octreotide.

Source: ClinicalTrials.gov ↗

→

Clinical trials · Mecasermin

ClinicalTrials.gov record NCT01446783

PeptideScanner retained ClinicalTrials.gov record NCT01446783 at 2026-11-16T17:35:13.282Z. Its registry update date was 2012-11-20, and PeptideScanner's reviewed identity mapping was mecasermin.

Source: ClinicalTrials.gov ↗

→

Literature metadata · Hexarelin

Hexarelin, a growth hormone - releasing peptide, counteracts bone loss in gonadectomized male rats.

PubMed lists PMID 10512687 in Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 1999-08 (month precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Literature metadata · Hexarelin

Kinetics and disposition of hexarelin, a peptidic growth hormone secretagogue, in rats.

PubMed lists PMID 10611139 in Drug metabolism and disposition: the biological fate of chemicals as Journal Article, with publication-date metadata of 2000-01 (month precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Literature metadata · Mecasermin

Mecasermin (recombinant human insulin-like growth factor I).

PubMed lists PMID 19198769 in Advances in therapy as Journal Article, Review, with publication-date metadata of 2009-01-28 (day precision). PeptideScanner associated the retained record with the identity slug mecasermin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Literature metadata · Histrelin

A review of the use of histrelin acetate in the treatment of prostate cancer.

PubMed lists PMID 19228148 in BJU international as Journal Article, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2009-03 (month precision). PeptideScanner associated the retained record with the identity slug histrelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Literature metadata · Hexarelin

Hexarelin, a growth hormone-releasing peptide, discloses protectant activity against cardiovascular damage in rats with isolated growth hormone deficiency.

PubMed lists PMID 9534309 in Cardiologia (Rome, Italy) as Journal Article, with publication-date metadata of 1997-11 (month precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Literature metadata · Hexarelin

Growth hormone status during long-term hexarelin therapy.

PubMed lists PMID 9589671 in The Journal of clinical endocrinology and metabolism as Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 1998-05 (month precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Literature metadata · Hexarelin

Partial recovery of skeletal muscle sodium channel properties in aged rats chronically treated with growth hormone or the GH-secretagogue hexarelin.

PubMed lists PMID 9694949 in The Journal of pharmacology and experimental therapeutics as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 1998-08 (month precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Literature metadata · Ipamorelin

PubMed record PMID 10373343

PeptideScanner retained PubMed bibliographic metadata for PMID 10373343 at 2026-07-30T22:15:26.481Z. PubMed recorded a metadata revision date of 2012-11-15 and an Entrez history date of 1999-06-22. PeptideScanner associated this retained record with the identity slug ipamorelin. These dates describe PubMed metadata history, not the article's original publication date.

Source: PubMed ↗

→

Literature metadata · Epitalon

PubMed record PMID 12195242

PeptideScanner retained PubMed bibliographic metadata for PMID 12195242 at 2026-07-30T22:15:26.486Z. PubMed recorded a metadata revision date of 2012-11-15 and an Entrez history date of 2002-08-27. PeptideScanner associated this retained record with the identity slug epitalon. These dates describe PubMed metadata history, not the article's original publication date.

Source: PubMed ↗

→

Literature metadata · Epitalon

PubMed record PMID 12500162

PeptideScanner retained PubMed bibliographic metadata for PMID 12500162 at 2026-07-30T22:15:26.487Z. PubMed recorded a metadata revision date of 2012-11-15 and an Entrez history date of 2002-12-25. PeptideScanner associated this retained record with the identity slug epitalon. These dates describe PubMed metadata history, not the article's original publication date.

Source: PubMed ↗

→

Literature metadata · Epitalon

PubMed record PMID 12500171

PeptideScanner retained PubMed bibliographic metadata for PMID 12500171 at 2026-07-30T22:15:26.487Z. PubMed recorded a metadata revision date of 2012-11-15 and an Entrez history date of 2002-12-25. PeptideScanner associated this retained record with the identity slug epitalon. These dates describe PubMed metadata history, not the article's original publication date.

Source: PubMed ↗

→

Literature metadata · Epitalon

PubMed record PMID 16634527

PeptideScanner retained PubMed bibliographic metadata for PMID 16634527 at 2026-07-30T22:15:26.490Z. PubMed recorded a metadata revision date of 2012-11-15 and an Entrez history date of 2006-04-26. PeptideScanner associated this retained record with the identity slug epitalon. These dates describe PubMed metadata history, not the article's original publication date.

Source: PubMed ↗

→

Clinical trials · Glatiramer acetate

ClinicalTrials.gov record NCT00475865

PeptideScanner retained ClinicalTrials.gov record NCT00475865 at 2026-11-16T17:42:50.457Z. Its registry update date was 2012-11-06, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.

Source: ClinicalTrials.gov ↗

→

October 2012

2 records

Regulatory · Triptorelin

Federal Register rule 2012-25989

The Federal Register published rule 2012-25989, attributed to FDA and its parent HHS department, on 2012-10-23. Its official title is “New Animal Drugs; Approvals; Changes of Sponsor; Change of Sponsor's Name; Change of Sponsor's Address; Alfaxalone; Ivermectin and Clorsulon; Narasin; Triptorelin,” and PeptideScanner's exact reviewed identity mapping connects the document to Triptorelin.

Source: Federal Register via GovInfo ↗

→

Regulatory · Pasireotide

Federal Register notice 2012-25483

The Federal Register published notice 2012-25483, attributed to FDA and its parent HHS department, on 2012-10-17. Its official title is “Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Pasireotide.

Source: Federal Register via GovInfo ↗

→

September 2012

7 records

Clinical trials · Liraglutide

ClinicalTrials.gov record NCT01695109

PeptideScanner retained ClinicalTrials.gov record NCT01695109 at 2026-07-30T22:14:20.912Z. Its registry update date was 2012-09-27, and PeptideScanner's reviewed identity mapping was liraglutide.

Source: ClinicalTrials.gov ↗

→

Literature metadata · Teriparatide

PubMed record PMID 22986396

PeptideScanner retained PubMed bibliographic metadata for PMID 22986396 at 2026-07-30T22:15:26.556Z. PubMed recorded a metadata revision date of 2012-09-18 and an Entrez history date of 2012-09-19. PeptideScanner associated this retained record with the identity slug teriparatide. These dates describe PubMed metadata history, not the article's original publication date.

Source: PubMed ↗

→

Regulatory · Calcitonin salmon

Federal Register notice 2012-22658

The Federal Register published notice 2012-22658, attributed to FDA and its parent HHS department, on 2012-09-14. Its official title is “Draft and Revised Draft Guidances for Industry Describing Product-Specific Bioequivalence Recommendations; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Calcitonin salmon.

Source: Federal Register via GovInfo ↗

→

Regulatory · Oxytocin

Federal Register notice 2012-22195

The Federal Register published notice 2012-22195, attributed to FDA and its parent HHS department, on 2012-09-10. Its official title is “Withdrawal of Approval of New Animal Drug Applications; Chorionic Gonadotropin; Naloxone; Oxymorphone; Oxytocin,” and PeptideScanner's exact reviewed identity mapping connects the document to Oxytocin.

Source: Federal Register via GovInfo ↗

→

Regulatory · Oxytocin

Federal Register rule 2012-22196

The Federal Register published rule 2012-22196, attributed to FDA and its parent HHS department, on 2012-09-10. Its official title is “New Animal Drugs; Chorionic Gonadotropin; Naloxone; Oxymorphone; Oxytocin,” and PeptideScanner's exact reviewed identity mapping connects the document to Oxytocin.

Source: Federal Register via GovInfo ↗

→

August 2012

5 records

Literature metadata · Exenatide

PubMed record PMID 22753275

PeptideScanner retained PubMed bibliographic metadata for PMID 22753275 at 2026-07-30T22:15:26.545Z. PubMed recorded a metadata revision date of 2012-08-23 and an Entrez history date of 2012-07-04. PeptideScanner associated this retained record with the identity slug exenatide. These dates describe PubMed metadata history, not the article's original publication date.

Source: PubMed ↗

→

Regulatory · Teduglutide

Federal Register notice 2012-20612

The Federal Register published notice 2012-20612, attributed to FDA and its parent HHS department, on 2012-08-22. Its official title is “Gastrointestinal Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Teduglutide.

Source: Federal Register via GovInfo ↗

→

Clinical trials · Peginesatide

ClinicalTrials.gov record NCT00752791

PeptideScanner retained ClinicalTrials.gov record NCT00752791 at 2026-11-16T17:45:11.119Z. Its registry update date was 2012-08-15, and PeptideScanner's reviewed identity mapping was peginesatide.

Source: ClinicalTrials.gov ↗

→

July 2012

5 records

Clinical trials · Peginesatide

ClinicalTrials.gov record NCT00752609

PeptideScanner retained ClinicalTrials.gov record NCT00752609 at 2026-11-16T17:45:11.119Z. Its registry update date was 2012-07-27, and PeptideScanner's reviewed identity mapping was peginesatide.

Source: ClinicalTrials.gov ↗

→

Clinical trials · Terlipressin

ClinicalTrials.gov record NCT01637454

PeptideScanner retained ClinicalTrials.gov record NCT01637454 at 2026-11-15T21:47:40.408Z. Its registry update date was 2012-07-11, and PeptideScanner's reviewed identity mapping was terlipressin.

Source: ClinicalTrials.gov ↗

→

June 2012

8 records

Clinical trials · Peginesatide

ClinicalTrials.gov record NCT00434330

PeptideScanner retained ClinicalTrials.gov record NCT00434330 at 2026-11-16T17:45:11.119Z. Its registry update date was 2012-06-29, and PeptideScanner's reviewed identity mapping was peginesatide.

Source: ClinicalTrials.gov ↗

→

Clinical trials · Peginesatide

ClinicalTrials.gov record NCT00680043

PeptideScanner retained ClinicalTrials.gov record NCT00680043 at 2026-11-16T17:45:11.119Z. Its registry update date was 2012-06-29, and PeptideScanner's reviewed identity mapping was peginesatide.

Source: ClinicalTrials.gov ↗

→

Clinical trials · Teriparatide

ClinicalTrials.gov record NCT01078805

PeptideScanner retained ClinicalTrials.gov record NCT01078805 at 2026-07-30T22:14:20.917Z. Its registry update date was 2012-06-26, and PeptideScanner's reviewed identity mapping was teriparatide.

Source: ClinicalTrials.gov ↗

→

Clinical trials · Glatiramer acetate

ClinicalTrials.gov record NCT00666224

PeptideScanner retained ClinicalTrials.gov record NCT00666224 at 2026-11-16T17:42:50.457Z. Its registry update date was 2012-06-25, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.

Source: ClinicalTrials.gov ↗

→

Literature metadata · PEG-MGF

[Expression of mechano-growth factor and its roles in tissue repairs and regeneration].

PubMed lists PMID 22702061 in Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery as English Abstract, Journal Article, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2012-05 (month precision). PeptideScanner associated the retained record with the identity slug peg-mgf. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

May 2012

8 records

Regulatory · Vasopressin

Federal Register notice 2012-12040

The Federal Register published notice 2012-12040, attributed to FDA and its parent HHS department, on 2012-05-18. Its official title is “Determination That PITRESSIN TANNATE IN OIL (Vasopressin Tannate) Injection, 5 Pressor Units/Milliliter, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Vasopressin.

Source: Federal Register via GovInfo ↗

→

Regulatory · Tesamorelin

Federal Register notice 2012-10808

The Federal Register published notice 2012-10808, attributed to FDA and its parent HHS department, on 2012-05-04. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; EGRIFTA,” and PeptideScanner's exact reviewed identity mapping connects the document to Tesamorelin.

Source: Federal Register via GovInfo ↗

→

Regulatory · Liraglutide

Federal Register notice 2012-10517

The Federal Register published notice 2012-10517, attributed to FDA and its parent HHS department, on 2012-05-02. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; Victoza,” and PeptideScanner's exact reviewed identity mapping connects the document to Liraglutide.

Source: Federal Register via GovInfo ↗

→

April 2012

6 records

Regulatory · Carfilzomib

Federal Register notice 2012-10154

The Federal Register published notice 2012-10154, attributed to FDA and its parent HHS department, on 2012-04-27. Its official title is “Oncologic Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Carfilzomib.

Source: Federal Register via GovInfo ↗

→

March 2012

4 records

Clinical trials · Thymosin alpha-1

ClinicalTrials.gov record NCT01031966

PeptideScanner retained ClinicalTrials.gov record NCT01031966 at 2026-11-15T22:10:40.222Z. Its registry update date was 2012-03-29, and PeptideScanner's reviewed identity mapping was thymosin-alpha-1.

Source: ClinicalTrials.gov ↗

→

Regulatory · Peginesatide

Drugs@FDA application NDA202799

The official Drugs@FDA dataset lists original submission 1 for NDA 202799 with status AP dated 2012-03-27, and names peginesatide acetate among the application record's active ingredients.

Source: Drugs@FDA via openFDA ↗

→

Regulatory · Secretin

Federal Register notice 2012-6971

The Federal Register published notice 2012-6971, attributed to FDA and its parent HHS department, on 2012-03-23. Its official title is “Gastrointestinal Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Secretin.

Source: Federal Register via GovInfo ↗

→

February 2012

6 records

Regulatory · Desmopressin

Federal Register notice 2012-4037

The Federal Register published notice 2012-4037, attributed to FDA and its parent HHS department, on 2012-02-22. Its official title is “Final Guidances for Industry Describing Product-Specific Bioequivalence Recommendations; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Desmopressin.

Source: Federal Register via GovInfo ↗

→

Clinical trials · Terlipressin

ClinicalTrials.gov record NCT01373606

PeptideScanner retained ClinicalTrials.gov record NCT01373606 at 2026-11-15T21:47:40.408Z. Its registry update date was 2012-02-14, and PeptideScanner's reviewed identity mapping was terlipressin.

Source: ClinicalTrials.gov ↗

→

Clinical trials · Octreotide

ClinicalTrials.gov record NCT00257426

PeptideScanner retained ClinicalTrials.gov record NCT00257426 at 2026-07-30T22:14:20.913Z. Its registry update date was 2012-02-14, and PeptideScanner's reviewed identity mapping was octreotide.

Source: ClinicalTrials.gov ↗

→

Literature metadata · Liraglutide

PubMed record PMID 20610447

PeptideScanner retained PubMed bibliographic metadata for PMID 20610447 at 2026-07-30T22:15:26.499Z. PubMed recorded a metadata revision date of 2012-02-09 and an Entrez history date of 2010-07-09. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date.

Source: PubMed ↗

→

Literature metadata · Exenatide

PubMed record PMID 20436114

PeptideScanner retained PubMed bibliographic metadata for PMID 20436114 at 2026-07-30T22:15:26.497Z. PubMed recorded a metadata revision date of 2012-02-09 and an Entrez history date of 2010-05-04. PeptideScanner associated this retained record with the identity slug exenatide. These dates describe PubMed metadata history, not the article's original publication date.

Source: PubMed ↗

→

Literature metadata · Secretin

Decoding the roles of pilotins and accessory proteins in secretin escort services.

PubMed lists PMID 22098485 in FEMS microbiology letters as Journal Article, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2011-12-08 (day precision). PeptideScanner associated the retained record with the identity slug secretin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

January 2012

4 records

Regulatory · Leuprolide + 1 more

Federal Register notice 2012-1433

The Federal Register published notice 2012-1433, attributed to FDA and its parent HHS department, on 2012-01-25. Its official title is “Draft and Revised Draft Guidances for Industry Describing Product-Specific Bioequivalence Recommendations; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide and Octreotide.

Source: Federal Register via GovInfo ↗

→

Clinical trials · Bivalirudin

ClinicalTrials.gov record NCT00079586

PeptideScanner retained ClinicalTrials.gov record NCT00079586 at 2026-11-15T21:58:19.888Z. Its registry update date was 2012-01-05, and PeptideScanner's reviewed identity mapping was bivalirudin.

Source: ClinicalTrials.gov ↗

→